Triple
T1351591
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Fampyra |
E28893
|
entity |
| Predicate | marketingAuthorisationHolder |
P26890
|
FINISHED |
| Object | Biogen Netherlands B.V. |
E3807
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Biogen Netherlands B.V. | Statement: [Fampyra, marketingAuthorisationHolder, Biogen Netherlands B.V.]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Biogen Netherlands B.V. Context triple: [Fampyra, marketingAuthorisationHolder, Biogen Netherlands B.V.]
-
A.
Biogen
chosen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
B.
Eisai and Biogen
Eisai and Biogen are pharmaceutical companies that collaborate on developing innovative therapies, particularly in the field of neurodegenerative diseases such as Alzheimer’s.
-
C.
Alkermes
Alkermes is a biopharmaceutical company that develops innovative medicines for central nervous system disorders and other serious chronic diseases.
-
D.
Lonza
Lonza is a global Swiss-based life sciences company specializing in pharmaceutical, biotech, and nutrition products and services, particularly in contract development and manufacturing.
-
E.
Eisai
Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: marketingAuthorisationHolder Context triple: [Fampyra, marketingAuthorisationHolder, Biogen Netherlands B.V.]
-
A.
patentHolder
Indicates that one entity legally owns the rights granted by a specific patent associated with another entity or invention.
-
B.
namingRightsHolder
Indicates which entity holds the official right to name or brand another entity (such as a venue, event, or asset).
-
C.
trademarkOwner
Indicates that one entity legally owns and holds the rights to a particular trademark associated with another entity or product.
-
D.
designatesAuthority
Indicates that one entity formally assigns or confers decision-making power or control over something to another entity.
-
E.
authorizesFundingFor
Indicates that one entity grants official approval or permission for financial resources to be provided to another entity or purpose.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69a498571d248190a0ac9eb02d97097f |
completed | March 1, 2026, 7:49 p.m. |
| NER | Named-entity recognition | batch_69a4c26b1b4881908ae4b1b2c9b268a0 |
completed | March 1, 2026, 10:49 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69acce6a1dd48190b17ac5a7cf3ab933 |
completed | March 8, 2026, 1:18 a.m. |
| PD | Predicate disambiguation | batch_69a4bef5857c81909ae984feb85a26ca |
completed | March 1, 2026, 10:34 p.m. |
| PDg | Predicate description generation | batch_69a4bf60545c8190901ccfb2cb7c4b41 |
completed | March 1, 2026, 10:36 p.m. |
Created at: March 1, 2026, 7:56 p.m.